IL6 and neoplasm: In vitro experiments and transcriptomic analysis demonstrated that the MUC16 acted on neutrophils by Siglec-9 leading to an inflammatory and immunosuppressive phenotype, with upregulation of inflammatory-related pathways overexpression of immunosuppressive molecules like IL-6 and PD-L1, which inhibited the tumor-killing activity of NK cells.